Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
08/05/2024 | 22:37 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
08/05/2024 | 22:00 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
07/05/2024 | 13:00 | Business Wire | Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
06/05/2024 | 22:05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
06/05/2024 | 22:01 | Business Wire | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
30/04/2024 | 13:10 | Business Wire | Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
30/04/2024 | 13:00 | Business Wire | Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
29/04/2024 | 13:00 | Business Wire | Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
17/04/2024 | 13:00 | Business Wire | Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
08/03/2024 | 23:30 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
06/03/2024 | 13:00 | Business Wire | Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
27/02/2024 | 19:11 | Edgar (US Regulatory) | Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
14/02/2024 | 20:26 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
09/02/2024 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
07/02/2024 | 22:01 | Business Wire | Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
06/02/2024 | 13:00 | Business Wire | Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
31/01/2024 | 13:00 | Business Wire | Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
26/01/2024 | 22:39 | Edgar (US Regulatory) | Form ARS - Annual Report to Security Holders | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
26/01/2024 | 22:37 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
26/01/2024 | 22:25 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
11/01/2024 | 22:15 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
04/01/2024 | 13:00 | Business Wire | Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
03/01/2024 | 13:00 | Business Wire | Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
12/12/2023 | 23:16 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
22/11/2023 | 22:38 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
22/11/2023 | 22:21 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
22/11/2023 | 22:12 | Edgar (US Regulatory) | Form POSASR - Post-effective Amendment to an automatic shelf registration statement | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
22/11/2023 | 13:00 | Business Wire | Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
20/11/2023 | 22:01 | Business Wire | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
20/11/2023 | 12:25 | IH Market News | Monday’s Wall Street Highlights: GM, Microsoft, Citigroup, Amazon, and more | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |